Supplemental material
Journal of Medical Economics
Volume 27, 2024 - Issue 1
Oncology
Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden
, 
, , , , , , , , & show all
Kate Youngb Merck Research Laboratories, Merck & Co., Inc, Rahway, NJ, USACorrespondence[email protected]
https://orcid.org/0000-0001-5637-9871View further author information
https://orcid.org/0000-0001-5637-9871View further author information, , Vimalanand Shrikant Prabhub Merck Research Laboratories, Merck & Co., Inc, Rahway, NJ, USAhttps://orcid.org/0000-0003-1358-8846View further author information
https://orcid.org/0000-0003-1358-8846View further author information, Christina Ljungcrantzc Market Access, MSD Sweden, Stockholm, Swedenhttps://orcid.org/0000-0003-2002-5507View further author information
https://orcid.org/0000-0003-2002-5507View further author information, , , Anna Giertze Real World Evidence and Analytics, Quantify Research, Health Economics, Stockholm, Swedenhttps://orcid.org/0009-0000-7364-6820View further author information
https://orcid.org/0009-0000-7364-6820View further author information, , & show all